Australia's most trusted
source of pharma news
Thursday, 26 February 2026
Posted 26 February 2026 PM
A non-opioid pain patch is headed Down Under after Clinect secured Australian rights to Grünenthal’s Qutenza.
Qutenza contains a high concentration (eight per cent) of capsaicin, the same active used in Actor Pharmaceuticals’ Zostrix cream and AFT Pharmaceuticals creams Zo-Rub HP and Zo-Rub Osteo.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.